This invention provides androgen receptor targeting agents (ARTA). The agentsdefine a new subclass of compounds, which are selective androgen receptormodulators (SARM). Several of the SARM compounds have been found to have anunexpected androgenic and anabolic activity of a nonsteroidal ligand for theandrogen receptor. Other SARM compounds have been found to have an unexpectedantiandrogenic activity of a nonsteroidal ligand for the androgen receptor.The SARM compounds, either alone or as a composition, are useful for a) malecontraception； b) treatment of a variety of hormone-related conditions, forexample conditions associated with Androgen Decline in Aging Male (ADAM), suchas fatigue, depression, decreased libido, sexual dysfunction, erectiledysfunction, hypogonadism, osteoporosis, hair loss, anemia, obesity,sarcopenia, osteopenia, osteoporosis, benign prostate hyperplasia, alterationsin mood and cognition and prostate cancer； c) treatment of conditionsassociated with Androgen Decline in Female (ADIF), such as sexual dysfunction,decreased sexual libido, hypogonadism, sarcopenia, osteopenia, osteoporosis,alterations in cognition and mood, depression, anemia, hair loss, obesity,endometriosis, breast cancer, uterine cancer and ovarian cancer； d) treatmentand/or prevention of acute and/or chronic muscular wasting conditions； e)preventing and/or treating dry eye conditions； f) oral androgen replacementtherapy； and/or g) decreasing the incidence of, halting or causing aregression of prostate cancer.
